NASDAQ:EXAS - EXACT Sciences Stock Price, Forecast & News

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

EXACT Sciences Co. (NASDAQ:EXAS) posted its quarterly earnings results on Tuesday, February, 11th. The medical research company reported $0.54 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.37) by $0.91. The medical research company had revenue of $295.58 million for the quarter, compared to analyst estimates of $294.39 million. EXACT Sciences had a negative return on equity of 28.15% and a negative net margin of 9.59%. View EXACT Sciences' Earnings History.

EXACT Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for EXACT Sciences.

EXACT Sciences updated its FY 2020 After-Hours earnings guidance on Tuesday, February, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.61-1.645 billion, compared to the consensus revenue estimate of $1.59 billion.

16 analysts have issued 1-year price objectives for EXACT Sciences' stock. Their forecasts range from $102.00 to $143.00. On average, they expect EXACT Sciences' stock price to reach $122.93 in the next year. This suggests a possible upside of 25.2% from the stock's current price. View Analyst Price Targets for EXACT Sciences.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for EXACT Sciences.

Media stories about EXAS stock have trended very negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. EXACT Sciences earned a daily sentiment score of -3.6 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for EXACT Sciences.

EXACT Sciences saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 15,120,000 shares, an increase of 5.1% from the January 15th total of 14,380,000 shares. Based on an average daily volume of 2,370,000 shares, the short-interest ratio is presently 6.4 days. Approximately 11.8% of the company's shares are short sold. View EXACT Sciences' Current Options Chain.

Some companies that are related to EXACT Sciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other EXACT Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Aduro BioTech (ADRO), salesforce.com (CRM), Paypal (PYPL), AT&T (T), Advanced Micro Devices (AMD) and Square (SQ).

EXACT Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Jennison Associates LLC (4.33%), Artisan Partners Limited Partnership (1.69%), Victory Capital Management Inc. (1.23%), Zevenbergen Capital Investments LLC (1.20%), Victory Capital Management Inc. (1.15%) and Eagle Asset Management Inc. (0.82%). Company insiders that own EXACT Sciences stock include D Scott Coward, G Bradley Cole, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Mark Stenhouse, Michael S Wyzga, Scott C Johnson and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.

EXAS stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, First Trust Advisors LP, Zevenbergen Capital Investments LLC, AJO LP, Dai Ichi Life Insurance Company Ltd, Victory Capital Management Inc., Eagle Asset Management Inc. and Nisa Investment Advisors LLC. Company insiders that have sold EXACT Sciences company stock in the last year include G Bradley Cole, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse and Scott C Johnson. View Insider Buying and Selling for EXACT Sciences.

EXAS stock was purchased by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Marshall Wace North America L.P., Factory Mutual Insurance Co., D1 Capital Partners L.P., Spyglass Capital Management LLC, Partner Fund Management L.P., Jennison Associates LLC and Eaton Vance Management. View Insider Buying and Selling for EXACT Sciences.

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EXAS stock can currently be purchased for approximately $98.18.

EXACT Sciences has a market capitalization of $12.75 billion and generates $876.29 million in revenue each year. The medical research company earns $-83,990,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. EXACT Sciences employs 1,977 workers across the globe.View Additional Information About EXACT Sciences.

The official website for EXACT Sciences is http://www.exactsciences.com/.

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-535-8815.